Printer Friendly

BIOPLASTY WITHDRAWS BREAST IMPLANTS OVERSEAS

 BIOPLASTY WITHDRAWS BREAST IMPLANTS OVERSEAS
 ST. PAUL, Minn., April 1 /PRNewswire/ -- Bioplasty, Inc.


(NASDAQ-NMS: BIOP), announced today that it has withdrawn from its foreign markets all MISTI(R) silicone gel-filled mammary prostheses and MISTI GOLD(TM) mammary prostheses. The removal is a result of the company's decision to leave the silicone gel-filled breast implant business and regulatory agency concerns about the company's breast implant supplier's manufacturing and record keeping practices.
 Bioplasty, Inc. expects a charge to operations in its third fiscal quarter of approximately $750,000 representing the write-off of all breast implant product on hand, and an additional undetermined amount for future returns from customers. Future sales of MISTI GOLD implants will resume upon the company's receipt of an approved IDE submission and export authorizations from the FDA.
 Timothy Lawin, the company's president and CEO, stated, "We are committed to bringing the MISTI GOLD mammary prostheses to the United States and overseas market. We believe the MISTI GOLD prostheses with its alternative non-silicone filling gel provides an attractive new technology to both plastic surgeons and their patients considering breast reconstruction or augmentation."
 Bioplasty, Inc. has more than 20 years of experience in the development, manufacturing and marketing of plastic surgery products worldwide. Bioplasty's stock is currently traded on NASDAQ National Market System under the symbol BIOP.
 -0- 4/1/92
 /CONTACT: Timothy P. Lawin or Donald A. Major, both of Bioplasty, 612-636-4112/
 (BIOP) CO: Bioplasty, Inc. ST: Minnesota IN: MTC SU:


KH -- MN015 -- 4054 04/01/92 16:40 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:251
Previous Article:IBM UNVEILS OS/2 2.0 TO NEW YORK PC USERS GROUP; OS/2 2.0 NYPC BULLETIN BOARD ESTABLISHED; LARGEST MEETING IN HISTORY OF NYPC USERS GROUP
Next Article:NEW FRAUD VICTIM ASSISTANCE DIVISION COMBATS CREDIT CRIME
Topics:


Related Articles
FDA PANEL RECOMMENDS SILICONE BREAST IMPLANTS REMAIN ON THE MARKET
INAMED BRINGS PATENT INFRINGEMENT SUIT AGAINST BIOPLASTY
BIOPLASTY, INC., ANNOUNCES RECEIPT OF PATENT INFRINGEMENT COMPLAINT
BIOPLASTY RECEIVES BREAST IMPLANT PATENT
FDA CALLS FOR A UNITED STATES MORATORIUM ON SILICONE GEL-FILLED BREAST IMPLANTS
BIOPLASTY SUBMITS INVESTIGATIONAL DEVICE EXEMPTION (IDE) FOR ITS MISTI GOLD BREAST IMPLANTS
UROPLASTY ANNOUNCES APPOINTMENT OF PRESIDENT AND CHIEF EXECUTIVE OFFICER
BIOPLASTY WITHDRAWS SUBMISSIONS FILED WITH FOOD AND DRUG ADMINISTRATION
BIOPLASTY ANNOUNCES APPROVAL OF MERGER WITH BIO-MANUFACTURING
BIOPLASTY ANNOUNCES THIRD QUARTER RESULTS OF OPERATIONS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters